Sutro Biopharma, Inc. (NASDAQ:STRO) Receives Consensus Recommendation of “Moderate Buy” from Brokerages

Sutro Biopharma, Inc. (NASDAQ:STRO) has been assigned an average rating of “Moderate Buy” from the eight ratings firms that are currently covering the stock, Marketbeat reports. One investment analyst has rated the stock with a hold recommendation and seven have issued a buy recommendation on the company. The average twelve-month target price among brokers that have updated their coverage on the stock in the last year is $11.13.

A number of brokerages have recently issued reports on STRO. HC Wainwright reiterated a “buy” rating and set a $12.00 price objective on shares of Sutro Biopharma in a report on Monday, November 18th. JMP Securities reiterated a “market outperform” rating and set a $17.00 price target on shares of Sutro Biopharma in a research note on Wednesday, December 11th. Wedbush reissued an “outperform” rating and set a $8.00 price objective on shares of Sutro Biopharma in a report on Tuesday, December 10th. Piper Sandler restated an “overweight” rating and issued a $11.00 target price on shares of Sutro Biopharma in a report on Friday, October 11th. Finally, Wells Fargo & Company decreased their price target on Sutro Biopharma from $5.00 to $4.00 and set an “equal weight” rating for the company in a report on Wednesday, December 11th.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently bought and sold shares of the business. Virtu Financial LLC bought a new stake in shares of Sutro Biopharma during the 3rd quarter worth $77,000. Barclays PLC raised its position in Sutro Biopharma by 385.3% in the third quarter. Barclays PLC now owns 273,019 shares of the company’s stock worth $944,000 after acquiring an additional 216,757 shares during the period. Geode Capital Management LLC raised its position in Sutro Biopharma by 7.7% in the third quarter. Geode Capital Management LLC now owns 1,856,956 shares of the company’s stock worth $6,426,000 after acquiring an additional 132,015 shares during the period. XTX Topco Ltd boosted its stake in Sutro Biopharma by 222.0% in the third quarter. XTX Topco Ltd now owns 104,200 shares of the company’s stock valued at $361,000 after acquiring an additional 71,844 shares during the last quarter. Finally, Jane Street Group LLC grew its position in shares of Sutro Biopharma by 30.7% during the 3rd quarter. Jane Street Group LLC now owns 108,192 shares of the company’s stock valued at $374,000 after acquiring an additional 25,416 shares during the period. Hedge funds and other institutional investors own 96.99% of the company’s stock.

Sutro Biopharma Stock Up 1.1 %

Shares of STRO opened at $1.85 on Friday. The business’s fifty day moving average is $2.42 and its 200 day moving average is $3.34. Sutro Biopharma has a 12-month low of $1.67 and a 12-month high of $6.13. The stock has a market cap of $152.55 million, a P/E ratio of -1.15 and a beta of 1.15.

About Sutro Biopharma

Sutro Biopharma, Inc operates as a clinical-stage oncology company. The company develops site-specific and novel-format antibody drug conjugates (ADCs) that enables its proprietary integrated cell-free protein synthesis platform, XpressCF and XpressCF+. Its product candidates include STRO-002, an ADC directed against folate receptor-alpha, which is in Phase II/III clinical trials for patients with ovarian and endometrial cancers; VAX-24 and Vax-31 pneumococcal conjugate vaccine candidates that is in Phase II/III clinical trials for the treatment of invasive pneumococcal disease; and MK-1484, a distinct cytokine derivative molecule that is in Phase I clinical study for the treatment of cancer.